The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
Pierre Coulie - One of the best experts on this subject based on the ideXlab platform.
-
A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
Immunogenetics, 1996Co-Authors: Jean Herman, Pierre Van Der Bruggen, Immanuel F. Luescher, Susanna Mandruzzato, Pedro Romero, Joëlle Thonnard, Katharina Fleischhauer, Thierry Boon, Pierre CoulieAbstract:The human MAGE3 gene is expressed in a significant proportion of tumors of various histological types, but is silent in normal adult tissues other than testis and placenta. Antigens encoded by MAGE3 may therefore be useful targets for specific antitumor immunization. Two Antigenic peptides encoded by the MAGE3 gene have been reported previously. One is presented to cytolytic T lymphocytes (CTL) by HLA-A1, the other by HLA-A2 molecules. Here we show that MAGE3 also codes for a peptide that is presented to CTL by HLA-B44. MAGE3 peptides containing the HLA-B44 peptide binding motif were synthesized. Peptide MEVDPIGHLY, which showed the strongest binding to HLA-B44, was used to stimulate blood T lymphocytes from normal HLA-B44 donors. CTL clones were obtained that recognized not only HLA-B44 cells sensitized with the peptide, but also HLA-B44 tumor cell lines expressing MAGE3. The proportion of metastatic melanomas expressing the MAGE3/HLA-B44 Antigen should amount to approximately 17% in the Caucasian population, since 24% of individuals carry the HLA-B44 allele and 76% of these tumors express MAGE3.
Jean Herman - One of the best experts on this subject based on the ideXlab platform.
-
A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
Immunogenetics, 1996Co-Authors: Jean Herman, Pierre Van Der Bruggen, Immanuel F. Luescher, Susanna Mandruzzato, Pedro Romero, Joëlle Thonnard, Katharina Fleischhauer, Thierry Boon, Pierre CoulieAbstract:The human MAGE3 gene is expressed in a significant proportion of tumors of various histological types, but is silent in normal adult tissues other than testis and placenta. Antigens encoded by MAGE3 may therefore be useful targets for specific antitumor immunization. Two Antigenic peptides encoded by the MAGE3 gene have been reported previously. One is presented to cytolytic T lymphocytes (CTL) by HLA-A1, the other by HLA-A2 molecules. Here we show that MAGE3 also codes for a peptide that is presented to CTL by HLA-B44. MAGE3 peptides containing the HLA-B44 peptide binding motif were synthesized. Peptide MEVDPIGHLY, which showed the strongest binding to HLA-B44, was used to stimulate blood T lymphocytes from normal HLA-B44 donors. CTL clones were obtained that recognized not only HLA-B44 cells sensitized with the peptide, but also HLA-B44 tumor cell lines expressing MAGE3. The proportion of metastatic melanomas expressing the MAGE3/HLA-B44 Antigen should amount to approximately 17% in the Caucasian population, since 24% of individuals carry the HLA-B44 allele and 76% of these tumors express MAGE3.
Jean Paul Vernant - One of the best experts on this subject based on the ideXlab platform.
-
A human minor histocompatibility Antigen which appears to segregate with the major histocompatibility complex.
Transplantation, 1994Co-Authors: Giovanna Vinci, Michel Masset, Gilbert Semana, Jean Paul VernantAbstract:We obtained a cell line (So1) from a patient who rejected a T-depleted allogeneic BMT. Cytotoxic activity by cell-mediated lympholysis was found using So1 as effector and EBV-transformed donor B cells as targets, but no lysis of the patient's pretransplantation cells and of an unrelated HLA-nonidentical subject was observed, suggesting it was related to recognition of a minor transplantation Antigen which could have contributed to rejection of the graft. To define the HLA-restricting element(s), cell-mediated lympholysis experiments were performed with several B cell lines as targets. So1 lysed only targets sharing an HLA-B44 Antigen with the patient, thus demonstrating that the minor transplantation Antigen recognized was restricted by HLA-B44. The absence of lysis against the patient's pretransplantation cells may be related to the absence of the minor Antigen, suggesting that the patient's cytotoxic lymphocytes able to recognize a minor transplantation Antigen on the donor cells contributed to the rejection of the HLA-identical graft. Mendelian segregation of this minor Antigen was found in familial studies. Lysis was observed with cells from members of 2 families who had an association of HLA-B44 Antigen in the haplotype and the minor Antigen, whereas in 2 other HLA-B44-positive families, no lysis was found, probably because this minor Antigen was absent. Furthermore, these family studies: (1) demonstrated that this minor Antigen segregates with the MHC, suggesting its localization on chromosome 6; and (2) showed a close relationship between the minor Antigen and HLA-B44, strongly suggesting a linkage disequilibrium between the minor Antigen and its restriction Antigen B44.
Joëlle Thonnard - One of the best experts on this subject based on the ideXlab platform.
-
A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
Immunogenetics, 1996Co-Authors: Jean Herman, Pierre Van Der Bruggen, Immanuel F. Luescher, Susanna Mandruzzato, Pedro Romero, Joëlle Thonnard, Katharina Fleischhauer, Thierry Boon, Pierre CoulieAbstract:The human MAGE3 gene is expressed in a significant proportion of tumors of various histological types, but is silent in normal adult tissues other than testis and placenta. Antigens encoded by MAGE3 may therefore be useful targets for specific antitumor immunization. Two Antigenic peptides encoded by the MAGE3 gene have been reported previously. One is presented to cytolytic T lymphocytes (CTL) by HLA-A1, the other by HLA-A2 molecules. Here we show that MAGE3 also codes for a peptide that is presented to CTL by HLA-B44. MAGE3 peptides containing the HLA-B44 peptide binding motif were synthesized. Peptide MEVDPIGHLY, which showed the strongest binding to HLA-B44, was used to stimulate blood T lymphocytes from normal HLA-B44 donors. CTL clones were obtained that recognized not only HLA-B44 cells sensitized with the peptide, but also HLA-B44 tumor cell lines expressing MAGE3. The proportion of metastatic melanomas expressing the MAGE3/HLA-B44 Antigen should amount to approximately 17% in the Caucasian population, since 24% of individuals carry the HLA-B44 allele and 76% of these tumors express MAGE3.
Katharina Fleischhauer - One of the best experts on this subject based on the ideXlab platform.
-
A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3.
Immunogenetics, 1996Co-Authors: Jean Herman, Pierre Van Der Bruggen, Immanuel F. Luescher, Susanna Mandruzzato, Pedro Romero, Joëlle Thonnard, Katharina Fleischhauer, Thierry Boon, Pierre CoulieAbstract:The human MAGE3 gene is expressed in a significant proportion of tumors of various histological types, but is silent in normal adult tissues other than testis and placenta. Antigens encoded by MAGE3 may therefore be useful targets for specific antitumor immunization. Two Antigenic peptides encoded by the MAGE3 gene have been reported previously. One is presented to cytolytic T lymphocytes (CTL) by HLA-A1, the other by HLA-A2 molecules. Here we show that MAGE3 also codes for a peptide that is presented to CTL by HLA-B44. MAGE3 peptides containing the HLA-B44 peptide binding motif were synthesized. Peptide MEVDPIGHLY, which showed the strongest binding to HLA-B44, was used to stimulate blood T lymphocytes from normal HLA-B44 donors. CTL clones were obtained that recognized not only HLA-B44 cells sensitized with the peptide, but also HLA-B44 tumor cell lines expressing MAGE3. The proportion of metastatic melanomas expressing the MAGE3/HLA-B44 Antigen should amount to approximately 17% in the Caucasian population, since 24% of individuals carry the HLA-B44 allele and 76% of these tumors express MAGE3.